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Background
Depression is an important health problem worldwide
due to significant disability that it causes, reduction of
quality of life, loss of work days, and even suicide. The
aim of our survey was to evaluate the overall utilization
and pattern of use of antidepressants in Serbia in a
comparison with Finland in 2010 and to propose appro-
priate interventions in Serbia on the basis of the results
obtained.
Methods
The data on utilization of antidepressant drugs (ATC
group N06) for 2010 were retrieved from the annual
reports of relevent public institutions in Serbia and Fin-
land. The ATC/DDD methodology was applied and the
results were expressed in defined daily doses per 1000
inhabitants per day (DID). As an indicator of the quality of
drug prescribing, the Drug Utilization 90% (DU90%)
method was used.
Results
An overall antidepressant consumption in 2010 appeared
to be 6-fold lower in Serbia (11.7 DID) in comparison with
Finland (68.8 DID). Selective serotonine reuptake inhibi-
tors (SSRIs) accounted for the majority of antidepressant
utilization in both countries (73.8% for Serbia and 63.9%
for Finland). Apart from that, the pattern of utilization of
the most frequently used SSRI drugs was different between
these countries. Sertraline accounted for the highest share
in Serbia (5.6 DID) while citalopram and escitalopram are
generally the most widely used drugs for the treatment of
depression in Finland (17.5 DID and 11.8 DID respec-
tively). In our country, the group of nonselective monoa-
mine reuptake inhibitors (13.1%) took the second place
that makes a notable difference in comparison with
Finland where the second-ranked group was other antide-
pressants (N06AX) (29.2%).
Conclusions
The differences between selected countries in antidepres-
sant utilization are partly consequential to different socioe-
conomic and health policy factors. The considerably lower
utilization of antidepressants in Serbia implies possible
underdiagnosing of affective disorders in general practice.
To reduce the serious consequences that may be caused in
that way, the early diagnosis and timely, adequate and
effective management and treatment of depression is
essential.
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